RPRX - Royalty Pharma plc Stock Analysis & Valuation

Royalty Pharma plc (RPRX) trades at $67.18 with an EquitAI Valuation DNA score of 2/10 and Quality score of 10/10. The company's trailing P/E ratio is 27.9x. These scores evaluate balance sheet leverage, free cash flow generation, and fundamental multiples against historical benchmarks.

Wall Street analysts have a consensus 12-month price target of $66.5 for Royalty Pharma plc (RPRX), representing an implied 1.0% downside from its current trading level of $67.18 with an average rating of Buy based on 3 analyst ratings. Individual analyst price targets range from a low of $66.0 to a high of $67.0, with a median forecast of $66.5. EquitAI benchmarks analyst consensus projections against intrinsic Financial DNA valuation pillars.

Royalty Pharma plc has an indicated annual dividend yield of 1.73%. Dividend stability is factored into its Income DNA pillar alongside free cash flow coverage.

EquitAI provides quantitative financial research, algorithmic DNA scores, and SEC contextual analytics for informational and research purposes. It does not constitute personalized financial advice or broker-dealer investment recommendations.